Ftse Mib
33.188,58
-1,05%
DAX
18.210,55
0,26%
S&P 500
5.482,87
0,09%
NASDAQ
17.858,68
0,30%
Bitcoin
61.442,75
1,04%
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Imunon Inc (IMNN) Imunon Inc (IMNN) Notizie

IMNN

Imunon (IMNN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:IMNN
DataOraFonteTitoloSimboloCompagnia
24/06/202414:30GlobeNewswire Inc.IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian CancerNASDAQ:IMNNImunon Inc
14/06/202412:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMNNImunon Inc
13/06/202415:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMNNImunon Inc
10/06/202420:00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IMNNImunon Inc
05/06/202414:30GlobeNewswire Inc.First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical TrialNASDAQ:IMNNImunon Inc
23/05/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IMNNImunon Inc
15/05/202422:16Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:IMNNImunon Inc
15/05/202414:30GlobeNewswire Inc.Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual MeetingNASDAQ:IMNNImunon Inc
13/05/202415:00GlobeNewswire Inc.IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine StudyNASDAQ:IMNNImunon Inc
13/05/202414:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMNNImunon Inc
13/05/202414:00GlobeNewswire Inc.IMUNON Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:IMNNImunon Inc
08/05/202414:00GlobeNewswire Inc.IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEONASDAQ:IMNNImunon Inc
06/05/202417:00GlobeNewswire Inc.IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024NASDAQ:IMNNImunon Inc
18/04/202414:30GlobeNewswire Inc.IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101NASDAQ:IMNNImunon Inc
11/04/202414:00GlobeNewswire Inc.IMUNON Reports Compliance with Nasdaq Listing RequirementsNASDAQ:IMNNImunon Inc
28/03/202413:00GlobeNewswire Inc.IMUNON Reports 2023 Financial Results and Provides Business UpdateNASDAQ:IMNNImunon Inc
25/03/202413:30GlobeNewswire Inc.IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating LossesNASDAQ:IMNNImunon Inc
21/03/202422:00GlobeNewswire Inc.IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024NASDAQ:IMNNImunon Inc
13/03/202413:00GlobeNewswire Inc.IMUNON Files IND Application to Begin Human Testing of IMNN-101NASDAQ:IMNNImunon Inc
12/03/202422:00GlobeNewswire Inc.IMUNON Announces Leadership ChangeNASDAQ:IMNNImunon Inc
29/02/202414:30GlobeNewswire Inc.Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5NASDAQ:IMNNImunon Inc
27/02/202414:30GlobeNewswire Inc.Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian CancerNASDAQ:IMNNImunon Inc
22/02/202414:00GlobeNewswire Inc.IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal VaccineNASDAQ:IMNNImunon Inc
09/02/202422:09Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:IMNNImunon Inc
20/12/202323:15Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:IMNNImunon Inc
11/12/202314:30GlobeNewswire Inc.IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:IMNNImunon Inc
14/11/202315:00GlobeNewswire Inc.IMUNON’s VP of R&D to Present at the Vaccines Summit-2023NASDAQ:IMNNImunon Inc
14/11/202314:00GlobeNewswire Inc.IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business UpdateNASDAQ:IMNNImunon Inc
07/11/202314:30GlobeNewswire Inc.IMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023NASDAQ:IMNNImunon Inc
23/10/202314:30GlobeNewswire Inc.IMUNON’s Chief Science Officer to Present at the 3rd International Vaccines CongressNASDAQ:IMNNImunon Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:IMNN

La tua Cronologia

BIT
STLAM
Stellantis NV
BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
CPR
Davide Campari
BIT
ENEL
Enel
BIT
ENI
Eni
BIT
STMMI
ST Microelectronics
BIT
BPE
Bper Banca
BIT
SPM
Saipem
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
SFER
Salvatore Ferragamo
BIT
RACE
Ferrari NV
BIT
TEN
Tenaris
BIT
SRG
Snam
BIT
LDO
Leonardo
BIT
MONC
Moncler
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network